|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
(State or other jurisdiction of incorporation or organization)
|
|
51-0263969
(I.R.S. Employer Identification No.)
|
|
|
|
6901 Professional Pkwy. East, Suite 200
Sarasota, Florida
(Address of principal executive offices)
|
|
34240
(Zip Code)
|
Large accelerated filer
|
Accelerated filer
|
|
|
Non-accelerated filer (Do not check if a smaller reporting company)
|
Smaller reporting company
|
☐ Emerging growth company
|
|
|
Page
|
PART I.
|
FINANCIAL INFORMATION
|
|
|
|
|
Item 1.
|
Financial Statements (unaudited):
|
|
|
|
|
|
Condensed Consolidated Statements of Earnings
|
3
|
|
|
|
|
Condensed Consolidated Statements of Comprehensive Income
|
4
|
|
|
|
|
Condensed Consolidated Balance Sheets
|
5
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows
|
6
|
|
|
|
|
Condensed Consolidated Statement of Changes in Stockholders' Equity
|
7
|
|
|
|
|
Notes to Condensed Consolidated Financial Statements
|
8
|
|
|
|
Item 2.
|
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
14 |
|
|
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
20 |
|
|
|
Item 4.
|
Controls and Procedures
|
20 |
|
|
|
PART II.
|
OTHER INFORMATION
|
|
|
|
|
Item 1.
|
Legal Proceedings
|
21 |
|
|
|
Item 1A.
|
Risk Factors
|
21 |
|
|
|
Item 6.
|
Exhibits
|
21 |
|
|
|
|
Signatures
|
22 |
PART I. |
FINANCIAL INFORMATION
|
ITEM 1. |
FINANCIAL STATEMENTS
|
|
Three months ended
|
|||||||
March 31,
|
||||||||
|
2017
|
2016
|
||||||
|
||||||||
Net sales
|
$
|
1,086,305
|
$
|
902,423
|
||||
Cost of sales
|
418,691
|
342,904
|
||||||
Gross profit
|
667,614
|
559,519
|
||||||
|
||||||||
Selling, general and administrative expenses
|
409,358
|
314,528
|
||||||
Income from operations
|
258,256
|
244,991
|
||||||
|
||||||||
Interest expense, net
|
45,865
|
27,413
|
||||||
Other expense, net
|
(1,047
|
)
|
(129
|
)
|
||||
|
||||||||
Earnings before income taxes
|
211,344
|
217,449
|
||||||
|
||||||||
Income taxes
|
53,273
|
66,033
|
||||||
|
||||||||
Net earnings
|
$
|
158,071
|
$
|
151,416
|
||||
|
||||||||
Earnings per share:
|
||||||||
Basic
|
$
|
1.55
|
$
|
1.50
|
||||
Diluted
|
1.53
|
1.48
|
||||||
|
||||||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
101,885
|
101,071
|
||||||
Diluted
|
103,078
|
102,318
|
||||||
|
||||||||
Dividends declared per common share
|
$
|
0.35
|
$
|
0.30
|
|
Three months ended
|
|||||||
March 31,
|
||||||||
|
2017
|
2016
|
||||||
|
||||||||
Net earnings
|
$
|
158,071
|
$
|
151,416
|
||||
|
||||||||
Other comprehensive income, net of tax:
|
||||||||
Foreign currency translation adjustments
|
30,412
|
1,743
|
||||||
Total other comprehensive income, net of tax
|
30,412
|
1,743
|
||||||
|
||||||||
Comprehensive income
|
$
|
188,483
|
$
|
153,159
|
|
March 31,
|
December 31,
|
||||||
2017
|
2016
|
|||||||
ASSETS:
|
||||||||
|
||||||||
Cash and cash equivalents
|
$
|
730,666
|
$
|
757,200
|
||||
Accounts receivable, net
|
549,838
|
619,854
|
||||||
Inventories, net
|
191,426
|
181,952
|
||||||
Unbilled receivables
|
143,589
|
129,965
|
||||||
Prepaid income taxes
|
28,100
|
31,679
|
||||||
Other current assets
|
69,004
|
55,851
|
||||||
Total current assets
|
1,712,623
|
1,776,501
|
||||||
|
||||||||
Property, plant and equipment, net
|
144,113
|
141,318
|
||||||
Goodwill
|
8,681,114
|
8,647,142
|
||||||
Other intangible assets, net
|
3,587,838
|
3,655,843
|
||||||
Deferred taxes
|
30,300
|
30,620
|
||||||
Other assets
|
74,066
|
73,503
|
||||||
|
||||||||
Total assets
|
$
|
14,230,054
|
$
|
14,324,927
|
||||
|
||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY:
|
||||||||
|
||||||||
Accounts payable
|
$
|
152,638
|
$
|
152,067
|
||||
Accrued compensation
|
131,584
|
161,730
|
||||||
Deferred revenue
|
513,820
|
488,399
|
||||||
Other accrued liabilities
|
251,298
|
219,339
|
||||||
Income taxes payable
|
88,126
|
22,762
|
||||||
Current portion of long-term debt, net
|
401,072
|
400,975
|
||||||
Total current liabilities
|
1,538,538
|
1,445,272
|
||||||
|
||||||||
Long-term debt, net of current portion
|
5,439,700
|
5,808,561
|
||||||
Deferred taxes
|
1,169,151
|
1,178,205
|
||||||
Other liabilities
|
111,875
|
104,024
|
||||||
Total liabilities
|
8,259,264
|
8,536,062
|
||||||
|
||||||||
Commitments and contingencies (Note 8)
|
||||||||
|
||||||||
Common stock
|
1,039
|
1,036
|
||||||
Additional paid-in capital
|
1,518,213
|
1,489,067
|
||||||
Retained earnings
|
4,764,711
|
4,642,402
|
||||||
Accumulated other comprehensive earnings
|
(294,327
|
)
|
(324,739
|
)
|
||||
Treasury stock
|
(18,846
|
)
|
(18,901
|
)
|
||||
Total stockholders' equity
|
5,970,790
|
5,788,865
|
||||||
|
||||||||
Total liabilities and stockholders' equity
|
$
|
14,230,054
|
$
|
14,324,927
|
|
Three months ended March 31,
|
|||||||
|
2017
|
2016
|
||||||
Cash flows from operating activities:
|
||||||||
Net earnings
|
$
|
158,071
|
$
|
151,416
|
||||
Adjustments to reconcile net earnings to cash flows from operating activities:
|
||||||||
Depreciation and amortization of property, plant and equipment
|
12,377
|
9,702
|
||||||
Amortization of intangible assets
|
72,998
|
49,549
|
||||||
Amortization of deferred financing costs
|
1,821
|
1,359
|
||||||
Non-cash stock compensation
|
21,049
|
18,979
|
||||||
Changes in operating assets and liabilities, net of acquired businesses:
|
||||||||
Accounts receivable
|
73,056
|
(16,355
|
)
|
|||||
Unbilled receivables
|
(13,520
|
)
|
2,296
|
|||||
Inventories
|
(7,905
|
)
|
(3,907
|
)
|
||||
Accounts payable and accrued liabilities
|
(2,223
|
)
|
(20,023
|
)
|
||||
Deferred revenue
|
34,308
|
292
|
||||||
Income taxes
|
39,013
|
20,127
|
||||||
Other, net
|
(10,828
|
)
|
(6,363
|
)
|
||||
Cash provided by operating activities
|
378,217
|
207,072
|
||||||
|
||||||||
Cash flows from investing activities:
|
||||||||
Acquisitions of businesses, net of cash acquired
|
(2,829
|
)
|
(265,248
|
)
|
||||
Capital expenditures
|
(14,930
|
)
|
(9,489
|
)
|
||||
Capitalized software expenditures
|
(3,169
|
)
|
(665
|
)
|
||||
Proceeds from sale of assets
|
109
|
673
|
||||||
Other, net
|
(500
|
)
|
773
|
|||||
Cash used in investing activities
|
(21,319
|
)
|
(273,956
|
)
|
||||
|
||||||||
Cash flows from financing activities:
|
||||||||
Payments under revolving line of credit, net
|
(370,000
|
)
|
(160,000
|
)
|
||||
Principal payments on convertible notes
|
-
|
(289
|
)
|
|||||
Cash premiums paid on convertible note conversions
|
-
|
(915
|
)
|
|||||
Cash dividends to stockholders
|
(35,443
|
)
|
(30,173
|
)
|
||||
Proceeds from stock based compensation, net
|
7,576
|
690
|
||||||
Treasury stock sales
|
1,032
|
879
|
||||||
Other
|
(250
|
)
|
(374
|
)
|
||||
Cash used in financing activities
|
(397,085
|
)
|
(190,182
|
)
|
||||
|
||||||||
Effect of foreign currency exchange rate changes on cash
|
13,653
|
1,588
|
||||||
|
||||||||
Net decrease in cash and cash equivalents
|
(26,534
|
)
|
(255,478
|
)
|
||||
|
||||||||
Cash and cash equivalents, beginning of period
|
757,200
|
778,511
|
||||||
|
||||||||
Cash and cash equivalents, end of period
|
$
|
730,666
|
$
|
523,033
|
|
Common
stock
|
Additional
paid-in
capital
|
Retained
earnings
|
Accumulated
other comprehensive earnings |
Treasury
stock
|
Total
|
||||||||||||||||||
Balances at December 31, 2016
|
$
|
1,036
|
$
|
1,489,067
|
$
|
4,642,402
|
$
|
(324,739
|
)
|
$
|
(18,901
|
)
|
$
|
5,788,865
|
||||||||||
|
||||||||||||||||||||||||
Net earnings
|
-
|
-
|
158,071
|
-
|
-
|
158,071
|
||||||||||||||||||
Stock option exercises
|
1
|
12,932
|
-
|
-
|
-
|
12,933
|
||||||||||||||||||
Treasury stock sold
|
-
|
977
|
-
|
-
|
55
|
1,032
|
||||||||||||||||||
Currency translation adjustments, net of $1,048 tax
|
-
|
-
|
-
|
30,412
|
-
|
30,412
|
||||||||||||||||||
Stock based compensation
|
-
|
20,598
|
-
|
-
|
-
|
20,598
|
||||||||||||||||||
Restricted stock activity
|
2
|
(5,361
|
)
|
-
|
-
|
-
|
(5,359
|
)
|
||||||||||||||||
Dividends declared
|
-
|
-
|
(35,762
|
)
|
-
|
-
|
(35,762
|
)
|
||||||||||||||||
Balances at March 31, 2017
|
$
|
1,039
|
$
|
1,518,213
|
$
|
4,764,711
|
$
|
(294,327
|
)
|
$
|
(18,846
|
)
|
$
|
5,970,790
|
1. |
Basis of Presentation
|
2. |
Recent Accounting Pronouncements
|
3. |
Earnings Per Share
|
|
Three months ended
|
|||||||
March 31,
|
||||||||
|
2017
|
2016
|
||||||
Basic shares outstanding
|
101,885
|
101,071
|
||||||
Effect of potential common stock:
|
||||||||
Common stock awards
|
1,193
|
1,172
|
||||||
Senior subordinated convertible notes
|
-
|
75
|
||||||
Diluted shares outstanding
|
103,078
|
102,318
|
4. |
Stock Based Compensation
|
|
Three months ended March 31,
|
|||||||
|
2017
|
2016
|
||||||
Stock based compensation
|
$
|
21,049
|
$
|
18,979
|
||||
Tax effect recognized in net income
|
7,367
|
6,643
|
|
Three months ended March 31,
|
|||||||
|
2017
|
2016
|
||||||
Risk-free interest rate (%)
|
2.09
|
1.41
|
||||||
Expected option life (years)
|
5.27
|
5.20
|
||||||
Expected volatility (%)
|
18.87
|
21.63
|
||||||
Expected dividend yield (%)
|
0.69
|
0.70
|
|
March 31,
|
December 31,
|
||||||
2017
|
2016
|
|||||||
Raw materials and supplies
|
$
|
119,711
|
$
|
113,632
|
||||
Work in process
|
26,589
|
24,290
|
||||||
Finished products
|
82,848
|
81,263
|
||||||
Inventory reserves
|
(37,722
|
)
|
(37,233
|
)
|
||||
|
$
|
191,426
|
$
|
181,952
|
6. |
Goodwill and Other Intangible Assets
|
|
Medical &
Scientific Imaging |
RF Technology
|
Industrial
Technology |
Energy Systems
& Controls |
Total
|
|||||||||||||||
Balances at December 31, 2016
|
$
|
3,185,071
|
$
|
4,687,670
|
$
|
363,978
|
$
|
410,423
|
$
|
8,647,142
|
||||||||||
Other
|
3,556
|
19,574
|
-
|
-
|
23,130
|
|||||||||||||||
Currency translation adjustments
|
3,225
|
2,903
|
3,090
|
1,624
|
10,842
|
|||||||||||||||
Balances at March 31, 2017
|
$
|
3,191,852
|
$
|
4,710,147
|
$
|
367,068
|
$
|
412,047
|
$
|
8,681,114
|
|
Cost
|
Accumulated
amortization
|
Net book
value
|
|||||||||
Assets subject to amortization:
|
||||||||||||
Customer related intangibles
|
$
|
3,272,081
|
$
|
(712,718
|
)
|
$
|
2,559,363
|
|||||
Unpatented technology
|
462,152
|
(144,025
|
)
|
318,127
|
||||||||
Software
|
184,761
|
(56,882
|
)
|
127,879
|
||||||||
Patents and other protective rights
|
24,656
|
(20,399
|
)
|
4,257
|
||||||||
Trade names
|
6,591
|
(653
|
)
|
5,938
|
||||||||
Assets not subject to amortization:
|
||||||||||||
Trade names
|
578,279
|
-
|
578,279
|
|||||||||
In process research and development
|
62,000
|
-
|
62,000
|
|||||||||
Balances at December 31, 2016
|
$
|
4,590,520
|
$
|
(934,677
|
)
|
$
|
3,655,843
|
|||||
Assets subject to amortization:
|
||||||||||||
Customer related intangibles
|
$
|
3,274,117
|
$
|
(764,054
|
)
|
$
|
2,510,063
|
|||||
Unpatented technology
|
463,399
|
(158,751
|
)
|
304,648
|
||||||||
Software
|
184,846
|
(63,850
|
)
|
120,996
|
||||||||
Patents and other protective rights
|
25,425
|
(20,625
|
)
|
4,800
|
||||||||
Trade names
|
6,598
|
(920
|
)
|
5,678
|
||||||||
Assets not subject to amortization:
|
||||||||||||
Trade names
|
579,653
|
-
|
579,653
|
|||||||||
In process research and development
|
62,000
|
-
|
62,000
|
|||||||||
Balances at March 31, 2017
|
$
|
4,596,038
|
$
|
(1,008,200
|
)
|
$
|
3,587,838
|
7. |
Fair Value of Financial Instruments
|
$400 million 1.850% senior notes due 2017
|
$
|
401
|
||
$800 million 2.050% senior notes due 2018
|
803
|
|||
$500 million 6.250% senior notes due 2019
|
547
|
|||
$600 million 3.000% senior notes due 2020
|
611
|
|||
$500 million 2.800% senior notes due 2021
|
500
|
|||
$500 million 3.125% senior notes due 2022
|
504
|
|||
$300 million 3.850% senior notes due 2025
|
304
|
|||
$700 million 3.800% senior notes due 2026
|
703
|
8. |
Contingencies
|
Balances at December 31, 2016
|
$
|
10,548
|
||
Additions charged to costs and expenses
|
3,967
|
|||
Deductions
|
(4,046
|
)
|
||
Other
|
49
|
|||
Balances at March 31, 2017
|
$
|
10,518
|
9. |
Business Segments
|
|
Three Months Ended March 31,
|
|||||||||||
|
2017
|
2016
|
Change
|
|||||||||
Net sales:
|
||||||||||||
Medical & Scientific Imaging
|
$
|
348,235
|
$
|
332,214
|
4.8
|
%
|
||||||
RF Technology
|
429,619
|
280,210
|
53.3
|
%
|
||||||||
Industrial Technology
|
183,404
|
171,235
|
7.1
|
%
|
||||||||
Energy Systems & Controls
|
125,047
|
118,764
|
5.3
|
%
|
||||||||
Total
|
$
|
1,086,305
|
$
|
902,423
|
20.4
|
%
|
||||||
Gross profit:
|
||||||||||||
Medical & Scientific Imaging
|
$
|
251,930
|
$
|
246,897
|
2.0
|
%
|
||||||
RF Technology
|
251,478
|
160,365
|
56.8
|
%
|
||||||||
Industrial Technology
|
93,151
|
86,020
|
8.3
|
%
|
||||||||
Energy Systems & Controls
|
71,055
|
66,237
|
7.3
|
%
|
||||||||
Total
|
$
|
667,614
|
$
|
559,519
|
19.3
|
%
|
||||||
Operating profit*:
|
||||||||||||
Medical & Scientific Imaging
|
$
|
119,793
|
$
|
114,456
|
4.7
|
%
|
||||||
RF Technology
|
88,984
|
88,766
|
0.2
|
%
|
||||||||
Industrial Technology
|
53,613
|
46,759
|
14.7
|
%
|
||||||||
Energy Systems & Controls
|
30,236
|
24,182
|
25.0
|
%
|
||||||||
Total
|
$
|
292,626
|
$
|
274,163
|
6.7
|
%
|
||||||
Long-lived assets:
|
||||||||||||
Medical & Scientific Imaging
|
$
|
44,689
|
$
|
40,621
|
10.0
|
%
|
||||||
RF Technology
|
76,652
|
30,828
|
148.6
|
%
|
||||||||
Industrial Technology
|
34,067
|
36,802
|
(7.4
|
)%
|
||||||||
Energy Systems & Controls
|
9,550
|
12,071
|
(20.9
|
)%
|
||||||||
Total
|
$
|
164,958
|
$
|
120,322
|
37.1
|
%
|
ITEM 2. |
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
● |
general economic conditions;
|
● |
difficulty making acquisitions and successfully integrating acquired businesses;
|
● |
any unforeseen liabilities associated with future acquisitions;
|
● |
limitations on our business imposed by our indebtedness;
|
● |
unfavorable changes in foreign exchange rates;
|
● |
difficulties associated with exports;
|
● |
risks and costs associated with our international sales and operations;
|
● |
rising interest rates;
|
● |
product liability and insurance risks;
|
● |
increased warranty exposure;
|
● |
future competition;
|
● |
the cyclical nature of some of our markets;
|
● |
reduction of business with large customers;
|
● |
risks associated with government contracts;
|
● |
changes in the supply of, or price for, labor, raw materials, parts and components;
|
● |
environmental compliance costs and liabilities;
|
● |
risks and costs associated with asbestos-related litigation;
|
● |
potential write-offs of our substantial goodwill and other intangible assets;
|
● |
our ability to successfully develop new products;
|
● |
failure to protect our intellectual property;
|
● |
the effect of, or change in, government regulations (including tax);
|
● |
economic disruption caused by terrorist attacks, including cybersecurity threats, health crises or other unforeseen events; and
|
● |
the factors discussed in other reports filed with the SEC.
|
Three months ended March 31,
|
||||||||
2017
|
2016
|
|||||||
Net sales:
|
||||||||
Medical & Scientific Imaging
|
$
|
348,235
|
$
|
332,214
|
||||
RF Technology
|
429,619
|
280,210
|
||||||
Industrial Technology
|
183,404
|
171,235
|
||||||
Energy Systems & Controls
|
125,047
|
118,764
|
||||||
Total
|
$
|
1,086,305
|
$
|
902,423
|
||||
Gross margin:
|
||||||||
Medical & Scientific Imaging
|
72.3
|
%
|
74.3
|
%
|
||||
RF Technology
|
58.5
|
57.2
|
||||||
Industrial Technology
|
50.8
|
50.2
|
||||||
Energy Systems & Controls
|
56.8
|
55.8
|
||||||
Total
|
61.5
|
62.0
|
||||||
Selling, general & administrative expenses:
|
||||||||
Medical & Scientific Imaging
|
37.9
|
%
|
39.9
|
%
|
||||
RF Technology
|
37.8
|
25.6
|
||||||
Industrial Technology
|
21.6
|
22.9
|
||||||
Energy Systems & Controls
|
32.6
|
35.4
|
||||||
Total
|
34.5
|
31.6
|
||||||
Segment operating margin:
|
||||||||
Medical & Scientific Imaging
|
34.4
|
%
|
34.5
|
%
|
||||
RF Technology
|
20.7
|
31.7
|
||||||
Industrial Technology
|
29.2
|
27.3
|
||||||
Energy Systems & Controls
|
24.2
|
20.4
|
||||||
Total
|
26.9
|
30.4
|
||||||
Corporate administrative expenses
|
(3.2
|
)
|
(3.2
|
)
|
||||
23.8
|
27.1
|
|||||||
Interest expense
|
(4.2
|
)
|
(3.0
|
)
|
||||
Other income/(expense)
|
(0.1
|
)
|
-
|
|||||
Earnings before income taxes
|
19.5
|
24.1
|
||||||
Income taxes
|
(4.9
|
)
|
(7.3
|
)
|
||||
Net earnings
|
14.6
|
%
|
16.8
|
%
|
Net orders booked for the
three months ended
|
Order backlog as of
|
|||||||||||||||
March 31,
|
March 31,
|
|||||||||||||||
2017
|
2016
|
2017
|
2016
|
|||||||||||||
(in thousands)
|
||||||||||||||||
Medical & Scientific Imaging
|
$
|
350,777
|
$
|
343,850
|
$
|
427,524
|
$
|
405,093
|
||||||||
RF Technology
|
441,289
|
281,125
|
975,826
|
539,164
|
||||||||||||
Industrial Technology
|
195,316
|
178,905
|
77,706
|
76,380
|
||||||||||||
Energy Systems & Controls
|
126,727
|
122,770
|
95,136
|
94,453
|
||||||||||||
Total
|
$
|
1,114,109
|
$
|
926,650
|
$
|
1,576,192
|
$
|
1,115,090
|
Three months ended March 31,
|
||||||||
Cash provided by/(used in):
|
2017
|
2016
|
||||||
Operating activities
|
$
|
378.2
|
$
|
207.1
|
||||
Investing activities
|
(21.3
|
)
|
(274.0
|
)
|
||||
Financing activities
|
(397.1
|
)
|
(190.2
|
)
|
$400 million 1.850% senior notes due 2017
|
$
|
400,000
|
||
$800 million 2.050% senior notes due 2018
|
800,000
|
|||
$500 million 6.250% senior notes due 2019
|
500,000
|
|||
$600 million 3.000% senior notes due 2020
|
600,000
|
|||
$500 million 2.800% senior notes due 2021
|
500,000
|
|||
$500 million 3.125% senior notes due 2022
|
500,000
|
|||
$300 million 3.850% senior notes due 2025
|
300,000
|
|||
$700 million 3.800% senior notes due 2026
|
700,000
|
|||
Revolving credit facility
|
1,560,000
|
|||
Deferred finance costs
|
(22,077
|
)
|
||
Other
|
2,849
|
|||
Total debt
|
5,840,772
|
|||
Less current portion
|
401,072
|
|||
Long-term debt, net of deferred finance costs
|
$
|
5,439,700
|
March 31, 2017
|
December 31, 2016
|
|||||||
Total debt
|
$
|
5,840,772
|
$
|
6,209,536
|
||||
Cash
|
(730,666
|
)
|
(757,200
|
)
|
||||
Net debt
|
5,110,106
|
5,452,336
|
||||||
Stockholders' equity
|
5,970,790
|
5,788,865
|
||||||
Total net capital
|
$
|
11,080,896
|
$
|
11,241,201
|
||||
Net debt / total net capital
|
46.1
|
%
|
48.5
|
%
|
ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 4. |
CONTROLS AND PROCEDURES
|
Part II. |
OTHER INFORMATION
|
Item 1. |
Legal Proceedings
|
Item 1A. |
Risk Factors
|
10.1
|
Roper Technologies, Inc. Amended and Restated Employee Stock Purchase Plan, filed herewith.
|
|
31.1
|
|
Rule 13a-14(a)/15d-14(a), Certification of the Chief Executive Officer, filed herewith.
|
|
|
|
31.2
|
|
Rule 13a-14(a)/15d-14(a), Certification of the Chief Financial Officer, filed herewith.
|
|
|
|
32.1
|
|
Section 1350 Certification of the Chief Executive and Chief Financial Officers, furnished herewith.
|
|
|
|
101.INS
|
|
XBRL Instance Document, filed herewith.
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document, filed herewith.
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document, filed herewith.
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document, filed herewith.
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document, filed herewith.
|
|
||
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document, filed herewith.
|
/s/ Brian D. Jellison
|
|
Chairman of the Board, President,
|
May 5, 2017
|
Brian D. Jellison
|
|
and Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
|
/s/ John Humphrey
|
|
Chief Financial Officer and
|
May 5, 2017
|
John Humphrey
|
|
Executive Vice President
|
|
|
|
(Principal Financial Officer)
|
|
/s/ Paul J. Soni
|
|
Vice President and Controller
|
May 5, 2017
|
Paul J. Soni
|
|
(Principal Accounting Officer)
|
|
Number
|
|
Exhibit
|
10.1
|
|
Roper Technologies, Inc. Amended and Restated Employee Stock Purchase Plan, filed herewith.
|
31.1
|
|
Rule 13a-14(a)/15d-14(a), Certification of the Chief Executive Officer, filed herewith.
|
|
|
|
31.2
|
|
Rule 13a-14(a)/15d-14(a), Certification of the Chief Financial Officer, filed herewith.
|
|
|
|
32.1
|
|
Section 1350 Certification of the Chief Executive and Chief Financial Officers, furnished herewith.
|
|
|
|
101.INS
|
|
XBRL Instance Document, filed herewith.
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document, filed herewith.
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document, filed herewith.
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document, filed herewith.
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document, filed herewith.
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document, filed herewith.
|
1.
|
Purpose
.
The purpose of the Roper Technologies, Inc
.
Employee Stock Purchase Plan (the "Plan") is to provide employees of the subsidiaries of Roper Technologies, Inc. (formerly known as Roper Industries, Inc
.
) (the "Company") with an opportunity to participate in the benefit of stock ownership and to acquire an interest in the Company through the purchase of common stock, $
.
01 par value per share, of the Company (the "Common Stock"). The Company intends the Plan to qualify as an employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (the "Code")
.
Accordingly, the provisions of the Plan shall be construed so as to extend and limit participation in a manner consistent with the requirements of Code Section 423.
|
2.
|
Definitions.
|
3.
|
Eligibility.
Any Employee who has been employed by a Plan Sponsor for at least six months immediately before the Beginning Date (defined below) of an Offering Period (defined below) shall be eligible to participate in the Plan for that Offering Period. Notwithstanding the six-month minimum employment requirement of the preceding sentence, for any Offering Period, the Company may establish a separate offering that is limited to the Employees of one or more Plan Sponsors who have been employed for a different minimum period (not to exceed two years), provided that any such minimum employment period is applied in a consistent manner to all Employees of each Plan Sponsor whose Employees are granted purchase rights for the applicable Offering Period pursuant to such separate offering
.
|
a.
|
the date of a withdrawal under Paragraph 10(a) or (b) below; or
|
b.
|
the date of a termination of employment from all Plan Sponsors
.
|
4.
|
Offering Period.
Offering Period shall mean each calendar quarter beginning with the calendar quarter commencing January 1, 2000 and each calendar quarter thereafter until the Plan is otherwise amended or terminated. Each Offering Period will begin on the first day of that period (the "Beginning Date") and end on the last day of that period (the
"
Exercise Date").
|
5.
|
Participation
.
The Company will make available to each eligible Employee an authorization notice (the "Authorization") which must be completed to effect his or her right to commence participation in the Plan. An eligible Employee may become a participant for an Offering Period by completing the Authorization and delivering same to the Company at least one day prior to the appropriate Beginning Date
.
All employees granted purchase rights under the Plan shall have the same rights and privileges, except that the amount of Common Stock which may be purchased under such rights may vary in a uniform manner according to Compensation.
|
6.
|
Method of Payment.
A participant may contribute to the Plan through payroll deductions
,
as follows
:
|
a.
|
A participant shall elect on the Authorization to have deduction made from the participant's Compensation for the Offering Period at a rate expressed as a percentage of Compensation in whole number increments which is at least one percent (1%), but not in excess of ten percent (10%), of the participant's Compensation
.
|
b.
|
All payroll deductions made for a participant shall be credited to the participant's account under the Plan. All payroll deductions made from participants' Compensation shall be commingled with the general assets of the Company and no separate fund shall be established
.
Participants' accounts are solely for bookkeeping purposes and the Company shall not be obligated to pay interest on any payroll deductions credited to participants' accounts.
|
c.
|
A participant may not alter the rate of payroll deductions during the Offering Period; however, an existing participant may change the rate of payroll deductions effective for the immediately succeeding Offering Period by filing a revised Authorization within the same deadline as applies to new participants for that Offering Period.
|
d.
|
Dividends paid on shares of Common Stock held by the custodian identified in Paragraph 9 for the benefit of a participant also shall be applied to the purchase of shares of Common Stock for the Offering Period in which the dividends are paid, unless the participant has withdrawn from the Plan or otherwise ceased to be an active participant (such dividends are referred to herein as 'Credited Dividends'). Credited Dividends shall be credited to the participant's bookkeeping account under the Plan and shall be commingled with the general assets of the Company. The Company shall not be obligated to pay interest on any such Credited Dividends.
|
7.
|
Granting of Purchase Rights.
As of the first day of each Offering Period, a participant shall be granted purchase rights for a number of shares of Common Stock or fraction thereof, subject to the adjustments provided for in Paragraph 11 (a) below, determined according to the following procedure:
|
a.
|
Step 1
-
Determine the amount of the participant's payroll deduction and Credited Dividends during the Offering Period;
|
b.
|
Step 2
-
Determine the amount which represents the Purchase Price (as defined below); and
|
c.
|
Step 3
-
Divide the amount determined in Step 1 by the amount determined in Step 2.
|
8.
|
Exercise of Purchase Rights.
Unless a timely withdrawal has been effected pursuant to Paragraph 10 below, a participant's rights for the purchase of shares of Common Stock during an Offering Period will be automatically exercised on the Exercise Date (or the immediately preceding date, where applicable pursuant to Section 7(d)) for that Offering Period for the purchase of the maximum number of full and fractional shares which the sum of the payroll deductions and Credited Dividends credited to the participant's account on that Exercise Date can purchase at the Purchase Price. The applicable Plan Sponsor may make such provisions and take such action as it deems necessary or appropriate for the withholding of taxes and/or social insurance contributions which may be required under applicable law, including the withholding of such taxes from other compensation payable to the participant. Each participant, however, shall be responsible for the payment of all individual tax and social insurance contribution liabilities under the Plan.
|
9.
|
Delivery.
As soon as administratively feasible after the end of each Exercise Date, the Company shall deliver to a custodian designated by the Plan Administrator, the shares of Common Stock purchased upon the exercise of the purchase rights. A participant shall not be allowed to sell, assign, pledge or otherwise transfer any shares of Common Stock purchased by him or her under the Plan until the expiration of fifteen (15) months from the last day of the Offering Period for which such shares were acquired (the "Applicable Restriction Period") except as contemplated by Paragraph 13 upon the death of a participant. Once any Applicable Restriction Period has expired, a participant may elect at any time thereafter to have the applicable shares of Common Stock (rounded down to the nearest whole share), plus a cash amount equal to the fair market value of any fractional share, delivered to the participant or to an account established by the participant with any brokerage firm.
|
10.
|
Withdrawal.
A participant will be deemed to have elected to participate in each subsequent Offering Period following his or her initial election to participate in the Plan, unless (i) a written withdrawal notice is delivered to the Plan Administrator at least one week prior to the Beginning Date of an immediately succeeding Offering Period for which the participant desires to withdraw from the Plan, and (ii) the participant provides any other information in accordance with the procedures designated by the Plan Administrator.
|
11.
|
Stock.
The maximum aggregate number of shares of Common Stock to be sold to participants under the Plan shall be 1,000,000 (which number reflects the 2-for-1 stock split on August 29, 2005) shares, subject to further adjustment upon changes in capitalization of the Company as provided in Paragraph 15 below. The shares of Common Stock to be sold to participants under the Plan, may, at the election of the Company, include treasury shares, shares originally issued for such purpose, or shares purchased in the open market. If the total number of shares of Common Stock then available under the Plan for which purchase rights are to be exercised in accordance with Paragraph 8 exceeds the number of such shares then available under the Plan, the Company shall make a pro rata allocation of the shares available in as nearly a uniform manner as shall be practicable and as it shall determine to be equitable. If purchase rights expire or terminate for any reason without being exercised in full, the unpurchased shares subject to the rights shall again be available for the purposes of the Plan.
|
12.
|
Administration.
The Plan shall be administered by the Company (the "Plan Administrator"). The Plan Administrator shall be vested with full authority to make, administer and interpret such rules and regulations as it deems necessary to administer the Plan, and any determination or action of the Plan Administrator in connection with the interpretation or administration of the Plan shall be final and binding upon all participants and any and all persons claiming under or through any participant.
|
13.
|
Designation of Beneficiary
.
A participant may file with the Plan Administrator a written designation of a beneficiary who is to receive any cash to his or her credit under the Plan in the event of the participant's death before an Exercise Date, or any shares of Common Stock and cash to his or her credit under the Plan in the event of the participant's death on or after an Exercise Date but prior to the delivery of such shares and cash. A beneficiary may be changed by the participant at any time by notice in writing to the Plan Administrator.
|
14.
|
Transferability.
Neither payroll deductions or Credited Dividends credited to a participant's account nor any rights with regard to the exercise of purchase rights or rights to receive any shares or cash under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way by the participant. Any attempted assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with Paragraph 10 above
.
|
15.
|
Adjustments Upon Changes in Capitalization.
In the event that the outstanding shares of Common Stock of the Company are hereafter increased or decreased or changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a recapitalization, reclassification, stock split, combination of shares or dividend payable in shares of Common Stock, an appropriate adjustment shall automatically be made to the number and kind of shares available for the granting of purchase rights, or as to which outstanding purchase rights shall be exercisable, and to the Purchase Price.
|
16.
|
Amendment or Termination.
The Board of Directors of the Company may at any time terminate or amend the Plan. The cash balances, Credited Dividends and shares of Common Stock (rounded down to the nearest whole share), plus a cash amount equal to the fair market value of any fractional share
,
credited to participants' accounts as of the date of any Plan termination shall be delivered to those participants as soon as administratively feasible following the effective date of the Plan
'
s termination.
|
17.
|
Notices.
All notices or other communications by a participant to the Plan Administrator under or in connection with the Plan shall be deemed to have been duly given when received by the Secretary of the Company or when received in the form specified by the Company at the location, or by the person
,
designated by the Company for the receipt thereof
.
|
18.
|
No Contract.
This Plan shall not be deemed to constitute a contract between the Company or any Subsidiary and any eligible Employee or to be a consideration or an inducement for the employment of any Employee. Nothing contained in this Plan shall be deemed to give any Employee the right to be retained in the service of the Company or"any Subsidiary or to interfere with the right of the Company or any Subsidiary to discharge any Employee at any time regardless of the effect which such discharge shall have upon him or her or as a participant of the Plan.
|
19.
|
Waiver.
No liability whatever shall attach to or be incurred by any past present or future shareholders, officers or directors, as such, of the Company or any Subsidiary, under or by reason of any of the terms, conditions or agreements contained in this Plan or implied, and any and all liabilities of, and any and all rights and claims against, the Company or any Subsidiary
,
or any shareholder, officer or director as such, whether arising at common law or in equity or created by statute or constitution or otherwise, pertaining to this Plan, are hereby expressly waived and released by every eligible Employee as a part of the consideration for any benefits by the Company under this Plan.
|
20.
|
Securities Law Restrictions
.
Shares of Common Stock shall not be issued under the Plan unless (a) the exercise of the related purchase right and the issuance and delivery of the shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, and any rules and regulations promulgated pursuant to such laws and with the requirements of any stock exchange upon which the shares may then be listed; and (b) the express approval of counsel for the Company with respect to such compliance is first obtained. The Company reserves the right to place an appropriate legend on any certificate representing shares of Common Stock issuable under the Plan with any such legend reflecting restrictions on the transfer of the shares as may be necessary to assure the availability of applicable exemptions under federal and state securities laws.
|
21.
|
Approval of Shareholders.
The Plan was approved by the shareholders of the Company on March 17, 2000, which was within twelve (12) months after the adoption of the Plan by the Board of Directors of the Company.
|
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 5, 2017
|
/s/ Brian D. Jellison
|
|
Brian D. Jellison
|
|
Chairman of the Board, President and
|
|
Chief Executive Officer
|
(Principal Executive Officer) |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 5, 2017
|
/s/ John Humphrey
|
|
John Humphrey
|
|
Executive Vice President and
|
|
Chief Financial Officer
|
(Principal Financial Officer) |
1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 5, 2017
|
/s/ Brian D. Jellison
|
|
|
Brian D. Jellison
|
|
|
Chairman of the Board, President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ John Humphrey
|
|
|
John Humphrey
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
(Principal Financial Officer)
|
|